Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510335 · ClinicalTrials.gov registry record · NA
Lavender Essential Oil-based Product System for Sleep
A NA study, sponsored by dōTERRA International.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT06510335: Completed NA study, sponsored by dōTERRA International.
NCT06510335 is a NA study that has completed, run by dōTERRA International. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06510335, a NA study, has completed, sponsored by dōTERRA International.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn whether lavender essential oil-based product system can affect gene expression, serum protein markers, and sleep quality in healthy volunteers. The main questions this study aims to answer are: * Does the lavender essential oil-based product system affect gene expression and protein markers as measured in blood? * Does the lavender essential oil-based product system affect subjective quality of life and sleep assessments? * Is daily use of the product system safe, as measured by laboratory tests and adverse events? The lavender essential oil-based product system contains three components: an essential oil blend, a topical stick, and a dietary supplement. Participants will: * Receive a fitness tracker to monitor their sleep and physical activity. * Use the lavender essential oil-based product system for six weeks total according to this schedule: * 1 week: Essential oil blend * 1 week: Essential oil blend + topical stick * 4 weeks: Essential oil blend + topical stick + dietary supplement * Attend two study visits in which they provide blood and urine samples, and complete subjective sleep and quality of life assessments * Complete weekly subjective sleep assessments from home
Primary Outcome
Gene expression analysis refers to a genome-wide quantification of methylation. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another.
Interventions
- OTHER Lavender essential oil-based product system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2023-08-11 |
| Phase | NA |
What the finished NCT06510335 record still lists
NCT06510335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Lavender essential oil-based product system is the first listed.
NCT06510335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06510335 about?
NCT06510335 is a clinical study titled "Lavender Essential Oil-based Product System for Sleep". The goal of this clinical trial is to learn whether lavender essential oil-based product system can affect gene expression, serum protein markers, and sleep quality in healthy volunteers. The main questions this study aims to answer are: * Does the lavender essential oil-based product system affect...
What is the current status of trial NCT06510335?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2023-06-01. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT06510335?
The interventions under investigation include: Lavender essential oil-based product system (OTHER).
Who is sponsoring clinical trial NCT06510335?
This trial is sponsored by dōTERRA International, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06510335's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI